Myers Stephen P, Mulder Ann M, Baker Don G, Robinson Shelley R, Rolfe Margaret I, Brooks Lyndon, Fitton J Helen
NatMed-Research Unit, Southern Cross University, Lismore, NSW, Australia.
University Centre for Rural Health, Sydney School of Public Health, The University of Sydney, Lismore, NSW, Australia.
Biologics. 2016 May 26;10:81-8. doi: 10.2147/BTT.S95165. eCollection 2016.
Preliminary investigation of a fucoidan with demonstrated reduction in the symptoms of osteoarthritis (OA) of the hip and knee.
A double-blind randomized controlled trial was carried out to determine the safety and efficacy of a 300 mg dose of a Fucus vesiculosus extract (85% fucoidan) over a 12-week period in a population (n=122) with mild-to-moderate OA of the hip and knee as measured by the validated instrument "Comprehensive Osteoarthritis Test." Safety was measured by assessing cholesterol, liver function, renal function, and hematopoietic function, and closely monitoring adverse events.
Ninety-six participants completed the study. The reduction in symptoms of OA was not significantly different from the placebo response. There were no changes in the blood measurements that were of any clinical significance during the course of the study.
The F. vesiculosus fucoidan extract was safe and well tolerated. At a dose of 300 mg, the extract showed no difference in reduction of OA symptoms from the placebo.
对一种已证实可减轻髋部和膝部骨关节炎（OA）症状的岩藻聚糖进行初步研究。
开展了一项双盲随机对照试验，以确定在12周内，对于经有效工具“综合骨关节炎测试”测量为轻度至中度髋部和膝部OA的人群（n = 122），300毫克剂量的墨角藻提取物（85%岩藻聚糖）的安全性和有效性。通过评估胆固醇、肝功能、肾功能和造血功能以及密切监测不良事件来衡量安全性。
96名参与者完成了研究。OA症状的减轻与安慰剂反应无显著差异。在研究过程中，血液测量值没有出现具有任何临床意义的变化。
墨角藻岩藻聚糖提取物安全且耐受性良好。在300毫克剂量下，该提取物在减轻OA症状方面与安慰剂无差异。
